Screener
G&A at other companies
Other financials
Where this comes from
Reported directly by Intellia Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:GeneralAndAdministrativeExpense.
The source filing: Intellia Therapeutics’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:05 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-337952
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Collaboration revenue | $7,659 | $14,245 | $22,707 | $30,872 |
| Operating expenses: | ||||
| Research and development | 82,595 | 97,035 | 163,332 | 205,462 |
| General and administrative | 37,824 | 27,206 | 72,667 | 56,213 |
| Total operating expenses | 120,419 | 124,241 | 235,999 | 261,675 |
| Operating loss | (112,760) | (109,996) | (213,292) | (230,803) |
| Other income, net: | ||||
| Interest income | 5,797 | 7,402 | 11,002 | 16,005 |
Item 1. Financial Statements
FAQ
- What is Intellia Therapeutics's G&A?
- Intellia Therapeutics (NTLA) reported G&A of $37.82M in Q2 2026.
- How has Intellia Therapeutics's G&A changed year-over-year?
- Intellia Therapeutics's G&A increased by 39.0% year-over-year, from $27.21M to $37.82M.
- What is the long-term trend for Intellia Therapeutics's G&A?
- Over 4 years (2021 to 2025), Intellia Therapeutics's G&A has grown at a 13.9% compound annual growth rate (CAGR), from $71.1M to $119.8M.
- What does G&A mean?
- Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.
Ask your AI about Intellia Therapeutics's g&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude